Anti-C1S antibodies and methods of use

Patent metadata

Field	Value
Publication number	US-12084513-B2
Application number	US-201816763134-A
Country	US
Kind code	B2
Filing date	Nov 14, 2018
Priority date	Nov 14, 2017
Publication date	Sep 10, 2024
Grant date	Sep 10, 2024

Abstract

The invention provides anti-C1s antibodies and methods of using the same. The affinities of the antibodies to C1s depend on pH and other conditions. The invention also provides pharmaceutical formulations comprising the antibodies, and methods of treating an individual having a complement-mediated disease or disorder comprising administering the antibody to the individual. In addition, the binding affinity of the antibody at high and low pH was measured, and mice PK study was conducted on the antibodies, and pharmacokinetics parameters of the antibodies were evaluated in this application.

First claim

The invention claimed is:

1. An isolated antibody that binds to C1s, wherein the antibody comprises the HVR-H1 sequence of SEQ ID NO: 56, the HVR-H2 sequence of SEQ ID NO: 57 the HVR-H3 sequence of SEQ ID NO: 58, the HVR-L1 sequence of SEQ ID NO: 71, the HVR-L2 sequence of SEQ ID NO: 72, and the HVR-L3 sequence of SEQ ID NO: 73.

2. The antibody of claim 1 , comprising a VH sequence of SEQ ID NO:46 and a VL sequence of SEQ ID NO:51.

3. The antibody of claim 1 , comprising a variable region which comprises at least one histidine residue.

4. The antibody of claim 1 , wherein the antibody is a full-length antibody or a C1s binding antibody fragment.

5. The antibody of claim 4 , wherein the antibody is a full-length antibody.

6. The antibody of claim 5 , wherein the full-length antibody is a IgG1, IgG2, IgG3 or IgG4 antibody.

7. The antibody of claim 4 , wherein the wherein the antibody is a C1s binding antibody fragment.

8. The antibody of claim 7 , wherein the C1s binding antibody fragment is a Fv, Fab, Fab′, scFv, diabody, or F(ab′)2 fragment.

9. The antibody of claim 1 , wherein the antibody is a multispecific antibody.

10. The antibody of claim 9 , wherein the antibody is a bispecific antibody.

11. The antibody of claim 1 , wherein the antibody binds neonatal Fc receptor (FcRn).

12. The antibody of claim 1 , wherein the antibody contains a substitution that increases the binding of the antibody to Fc receptor (FcRn).

13. The antibody of claim 1 , wherein the antibody contains a substitution at one or more amino acid positions selected from 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 and 434 according to EU numbering.

14. The antibody of claim 1 , wherein the antibody comprises a Fc region or a variant Fc region.

15. The antibody of claim 14 , wherein the antibody comprises a variant Fc region.

16. The antibody of claim 15 , wherein the antibody has reduced effector function.

17. The antibody of claim 16 , wherein the antibody contains a substitution at one or more amino acid positions selected from 238, 265, 269, 270, 297, 327 and 329 according to European Union numbering.

18. The antibody of claim 17 , wherein the antibody has a substitution at two or more amino acid residues at positions selected from 265, 269, 270, 297 and 327 according to European Union numbering.

Assignees

• Chugai Pharmaceutical Co Ltd

Inventors

• Feng Shu
• Kuramochi Taichi
• Muraoka Masaru
• Takahashi Noriyuki

Classifications

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title